ABT vs BCO · P/E 25, rev $44.33B vs P/E 25, rev $5.01B
Abbott Laboratories (ABT) versus Brinks Company (BCO) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Brinks Company (BCO) is a security & protection services company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported BCO revenue for 2024-12-31 was $5.01B. Net income was $174.7M. Revenue was up 2.8% from 2023-12-31 to 2024-12-31. BCO currently screens at market cap $3.97B and trailing P/E 25.4.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. BCO currently screens at market cap $3.97B and trailing P/E 25.4.
Not investment advice. Open the ABT and BCO stock pages for the full models.
Not investment advice.